# Palbociclib in Metastatic Breast Cancer: Gene Polymorphism-based Study in Egyptian Patients.

> **NCT06338644** · — · NOT_YET_RECRUITING · sponsor: **Helwan University** · enrollment: 100 (estimated)

## Conditions studied

- Hormone-receptor-positive Breast Cancer
- Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
- Metastatic Breast Cancer

## Interventions

- **DRUG:** Palbociclib

## Key facts

- **NCT ID:** NCT06338644
- **Lead sponsor:** Helwan University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-07-01
- **Primary completion:** 2025-09-01
- **Final completion:** 2026-09-01
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2024-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06338644

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06338644, "Palbociclib in Metastatic Breast Cancer: Gene Polymorphism-based Study in Egyptian Patients.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06338644. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*